Novel Mutations on EGFR Leu792 Potentially Correlate to Acquired Resistance to Osimertinib in Advanced NSCLC

Journal of Thoracic Oncology

Volumn 12, Issue 6, 2017, Pages e65-e68

  Chen, Kai ^a   Zhou, Fei ^b   Shen, Wenxiang ^c   Jiang, Tao ^b   Wu, Xue ^d   Tong, Xiaoling ^d   Shao, Yang W ^d   Qin, Songbing ^a   Zhou, Caicun ^b  

^a THE FIRST AFFILIATED HOSPITAL OF SOOCHOW UNIVERSITY   (China)

^b TONGJI UNIVERSITY   (China)

^c KUNSHAN FIRST PEOPLE S HOSPITAL AFFILIATED TO JIANGSU UNIVERSITY   (China)

^d Geneseeq Technology Inc   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

CELL FREE DNA; DNA; EPIDERMAL GROWTH FACTOR RECEPTOR; GEFITINIB; OSIMERTINIB; UNCLASSIFIED DRUG; ANTINEOPLASTIC AGENT; EGFR PROTEIN, HUMAN; PIPERAZINE DERIVATIVE;

ARTICLE; CANCER CHEMOTHERAPY; CANCER STAGING; CASE REPORT; CORRELATION ANALYSIS; DNA EXTRACTION; DRUG RESPONSE; GENE FREQUENCY; GENETIC SCREENING; HUMAN; HUMAN TISSUE; LUNG ADENOCARCINOMA; MISSENSE MUTATION; MUTANT ALLELE FREQUENCY; NEXT GENERATION SEQUENCING; NON SMALL CELL LUNG CANCER; PLEURA EFFUSION; PRIORITY JOURNAL; THERAPY RESISTANCE; DRUG RESISTANCE; GENETICS; LUNG TUMOR; MUTATION; PATHOLOGY; PROGNOSIS;

ANTINEOPLASTIC AGENTS; CARCINOMA, NON-SMALL-CELL LUNG; DRUG RESISTANCE, NEOPLASM; HUMANS; LUNG NEOPLASMS; MUTATION; PIPERAZINES; PROGNOSIS; RECEPTOR, EPIDERMAL GROWTH FACTOR;

EID: 85018601700     PISSN: 15560864     EISSN: 15561380     Source Type: Journal    
DOI: 10.1016/j.jtho.2016.12.024     Document Type: Article

References (8)

1. Li, S., Li, L., Zhu, Y., et al. Coexistence of EGFR with KRAS, or BRAF, or PIK3CA somatic mutations in lung cancer: a comprehensive mutation profiling from 5125 Chinese cohorts. Br J Cancer 110 (2014), 2812–2820.
2. Sequist, L.V., Waltman, B.A., Dias-Santagata, D., et al. Genotypic and histological evolution of lung cancers acquiring resistance to EGFR inhibitors. Sci Transl Med, 3, 2011 75ra26.
3. Cross, D.A., Ashton, S.E., Ghiorghiu, S., et al. AZD9291, an irreversible EGFR TKI, overcomes T790M-mediated resistance to EGFR inhibitors in lung cancer. Cancer Discov 4 (2014), 1046–1061.
4. Jänne, P.A., Yang, J.C., Kim, D.W., et al. AZD9291 in EGFR inhibitor-resistant non-small-cell lung cancer. N Engl J Med 372 (2015), 1689–1699.
5. Thress, K.S., Paweletz, C.P., Felip, E., et al. Acquired EGFR C797S mutation mediates resistance to AZD9291 in non-small cell lung cancer harboring EGFR T790M. Nat Med 21 (2015), 560–562.
6. Ercan, D., Choi, H.G., Yun, C.H., et al. EGFR mutations and resistance to irreversible pyrimidine-based EGFR inhibitors. Clin Cancer Res 21 (2015), 3913–3923.
7. Niederst, M.J., Hu, H., Mulvey, H.E., et al. The allelic context of the C797S mutation acquired upon treatment with third-generation EGFR inhibitors impacts sensitivity to subsequent treatment strategies. Clin Cancer Res 21 (2015), 3924–3933.
8. Bersanelli, M., Minari, R., Bordi, P., et al. L718Q mutation as new mechanism of acquired resistance to AZD9291 in EGFR-mutated NSCLC. J Thorac Oncol 11 (2016), e121–e123.